Marisol Quintero, CEO of Highlight Therapeutics joins Proactive London for a catch up after a busy 2021.
At the end of the year, the firm reported excellent clinical data for BO-112 in patients with melanoma, Quintero talks through the next steps for the development of the treatment.
Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.